TABLE ONE
Draw in vitro and in vivo release profiles for the following formulations:
(Draw PEG)
Identify and draw the anticipated pharmacokinetic profiles resulting from oral administration of a stable, highly permeable drug with the provided in vitro release profiles, and include an immediate release version on the same graph.
A patient with a hereditary hormonal disorder requires peptide replacement therapy. The current treatment regimen involves subcutaneous injections twice daily (bid).
Task:
Draw the expected pharmacokinetic profile of this regimen over a one-week period.
On a separate graph, draw the anticipated pharmacokinetic profiles following a SINGLE administration of this peptide via each of the following routes:
Eye drops are a common form of medicine for ocular infections. Re-sketch a simpliefied version of the diagram below from the Discovery material without the labels and draw/label it instead to illustrate the possible paths that drug may take after topical administration ofa solution to the front the eye. gm
Refer to the main barriers to topical ocular delivery in this exercise. Where will most of the drug end up?
3. Based on your graph in task 2, identify which alternative route most closely resembles the pharmacokinetic profile of a single subcutaneous injection. Explain your reasoning using appropriate pharmacokinetic principles.